Vertex Pharmaceuticals (VRTX) Invested Capital (2009 - 2024)
Vertex Pharmaceuticals (VRTX) posted quarterly Invested Capital of $118.0 million for Q4 2024, down 72.35% year-over-year from $426.7 million in Q1 2024, and down 0.92% quarter-over-quarter from $119.1 million in Q3 2024.
Vertex Pharmaceuticals (VRTX) Invested Capital (2009 - 2024) Analysis & Trends
Vertex Pharmaceuticals' Invested Capital history runs 14 years deep, the most recent figure standing at $118.0 million for Q4 2024.
- In Q4 2024, Invested Capital fell 72.35% year-over-year to $118.0 million; the TTM figure through Sep 2025 stood at $118.0 million (down 78.38% YoY), while the FY2024 annual figure was $118.0 million, down 72.35% from the prior year.
- Invested Capital for Q4 2024 stood at $118.0 million, down from $119.1 million in the prior quarter.
- The five-year high for Invested Capital was $581.5 million in Q4 2020, with the low at $118.0 million in Q4 2024.
- The 5-year median for Invested Capital is $449.2 million (2022), against an average of $378.9 million.
- The sharpest annual moves came in 2020 and 2024: Invested Capital gained 0.72% in 2020, then slumped 72.35% in 2024.
- Vertex Pharmaceuticals' Invested Capital stood at $581.5 million in 2020, then declined by 4.26% to $556.7 million in 2021, then decreased by 15.29% to $471.6 million in 2022, then slipped by 9.52% to $426.7 million in 2023, then plunged by 72.35% to $118.0 million in 2024.
- Business Quant data shows VRTX's Invested Capital at $118.0 million in Q4 2024, $119.1 million in Q3 2024, and $426.7 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 190.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 380.00 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 118.00 Mn |
| Sep 30, 2024 | 119.10 Mn |
| Dec 31, 2023 | 426.70 Mn |
| Dec 31, 2022 | 471.60 Mn |
| Dec 31, 2021 | 556.70 Mn |
| Dec 31, 2020 | 581.50 Mn |
| Dec 31, 2019 | 577.37 Mn |
| Sep 30, 2019 | 578.62 Mn |
| Jun 30, 2019 | 588.58 Mn |
| Mar 31, 2019 | 596.11 Mn |
| Dec 31, 2018 | 596.64 Mn |
| Sep 30, 2018 | 94.09 Mn |
| Jun 30, 2018 | 471.80 Mn |
| Dec 31, 2017 | 472.07 Mn |
| Dec 31, 2016 | 75.00 Mn |
| Sep 30, 2016 | 297.75 Mn |
| Jun 30, 2016 | 221.58 Mn |
| Mar 31, 2016 | 146.25 Mn |
| Jun 30, 2015 | 42.87 Mn |
| Mar 31, 2015 | 28.53 Mn |